Masamichi Sugimoto
Chugai Pharmaceutical Co.
35 Papers
218 Citations
Masamichi Sugimoto is an academic researcher from Chugai Pharmaceutical Co.. The author has contributed to research in topics: Cancer & Antibody. The author has an hindex of 14, co-authored 33 publications.
Chat about Author
Papers
Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family.
Masahiko Mihara,Keiko Kasutani,Makoto Okazaki,Akito Nakamura,Shigeto Kawai,Masamichi Sugimoto,Yoshihiro Matsumoto,Yoshiyuki Ohsugi +7 more
TL;DR: Significant lines of evidence indicate that tocilizumab is able to bind to both sIL-6R and mIL- 6R and to inhibit IL-6 binding to its receptors, leading to the blockade of the IL- 6 signaling through both sil-6r and mil-7R, but not block the signaling of other IL-7 family cytokines.
332
Anti-glypican 3 antibodies cause ADCC against human hepatocellular carcinoma cells.
Kiyotaka Nakano,Tetsuro Orita,Jun-ichi Nezu,Takeshi Yoshino,Iwao Ohizumi,Masamichi Sugimoto,Koh Furugaki,Yasuko Kinoshita,Takahiro Ishiguro,Takao Hamakubo,Tatsuhiko Kodama,Hiroyuki Aburatani,Hisafumi Yamada-Okabe,Masayuki Tsuchiya +13 more
TL;DR: Using MRL/lpr mice, a series of anti-GPC3 monoclonal antibodies were generated, indicating that the C-terminal region of GPC3 serves as an epitope for mAb with ADCC and/or CDC inducing activities.
128
Generation of a humanized anti-glypican 3 antibody by CDR grafting and stability optimization
Kiyotaka Nakano,Takahiro Ishiguro,Hiroko Konishi,Megumi Tanaka,Masamichi Sugimoto,Izumi Sugo,Tomoyuki Igawa,Hiroyuki Tsunoda,Yasuko Kinoshita,Kiyoshi Habu,Tetsuro Orita,Masayuki Tsuchiya,Kunihiro Hattori,Hisafumi Yamada-Okabe +13 more
TL;DR: The resulting humanized anti-GPC3 antibody was as efficacious as chimeric GC33 against the HepG2 xenograft and is now being evaluated in clinical trials.
91
Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model
Chinami Masuda,Mieko Yanagisawa,Keigo Yorozu,Mitsue Kurasawa,Koh Furugaki,Nobuyuki Ishikura,Toshiki Iwai,Masamichi Sugimoto,Kaname Yamamoto +8 more
TL;DR: The erlotinib plus bevacizumab combination demonstrated promising efficacy in the B901L xenograft model of EGFR Mut+ NSCLC and elucidated the mode of action of this combination.
Topoisomerase I inhibitor, irinotecan, depletes regulatory T cells and up-regulates MHC class I and PD-L1 expression, resulting in a supra-additive antitumor effect when combined with anti-PD-L1 antibodies.
TL;DR: Results indicate that irinotecan may enhance the effect of T cell activation caused by anti-PD-L1 treatment by reducing Tregs and augmenting MHC class I–mediated tumor antigen presentation, and concurrent upregulation of PD-L 1 expression can be blocked by the anti- PD- L1 antibody.